Innate added to Goldman conviction list, shares soar

|About: Innate Pharma (IPHYF)|By:, SA News Editor

Goldman Sachs has initiated coverage on Innate Pharma (IPHYF) and added the company to its buy conviction list, sending its shares up 41% to €10.8 in Paris.

Goldman also gave Innate a price target of €18,

Innate specializes in the development of immunotherapy drugs for the treatment of cancer and inflammatory diseases.